Видео ютуба по тегу Dr Naval Daver

2025 Best of Hematology | Emerging Therapies for AML: Dr Naval Daver
2025 Best of Hematology | Emerging Therapies for AML: Dr Naval Daver
Game-Changing MDS Breakthroughs Revealed: Dr. Naval Daver Teases What’s Next
Game-Changing MDS Breakthroughs Revealed: Dr. Naval Daver Teases What’s Next
Navigating Acute Myeloid Leukemia Treatment: Therapy-Related & De Novo AML with Dr. Naval Daver
Navigating Acute Myeloid Leukemia Treatment: Therapy-Related & De Novo AML with Dr. Naval Daver
Dr. Naval Daver on Optimizing Therapy in CML and MPN
Dr. Naval Daver on Optimizing Therapy in CML and MPN
6. The Burden of AML - Mutations and Prognostic Implications, Dr. Naval Daver
6. The Burden of AML - Mutations and Prognostic Implications, Dr. Naval Daver
MDS/AML Overlap and Novel Therapies with Dr. Naval Daver
MDS/AML Overlap and Novel Therapies with Dr. Naval Daver
Virtual Round Table with MD Anderson Part I - Dr. Naval Daver - New & Emerging Therapies #AML
Virtual Round Table with MD Anderson Part I - Dr. Naval Daver - New & Emerging Therapies #AML
Ask the Expert: Naval Daver answers your AML questions at iwAL 2025
Ask the Expert: Naval Daver answers your AML questions at iwAL 2025
Acute myeloblastic leukemia - How do I manage in 2022? by Dr. Naval Daver, USA
Acute myeloblastic leukemia - How do I manage in 2022? by Dr. Naval Daver, USA
Enzomenib monotherapy in R/R AML: updated results from a Phase I/II study
Enzomenib monotherapy in R/R AML: updated results from a Phase I/II study
SOHO Saudi Arabia (DAY 3) - Dr Naval Daver
SOHO Saudi Arabia (DAY 3) - Dr Naval Daver
Dr. Daver on Immune Checkpoint Pathways in AML
Dr. Daver on Immune Checkpoint Pathways in AML
Improving Cure Rates in AML with Targeted Combinations
Improving Cure Rates in AML with Targeted Combinations
New Standards in Ph+ and High-Risk ALL
New Standards in Ph+ and High-Risk ALL
One big question with Naval Daver: what AML advance could transform frontline care in three years?
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Dr. Daver on the Advancing Treatment Landscape in AML
Dr. Daver on the Advancing Treatment Landscape in AML
Meet leukemia oncologist Naval Daver, M.D.
Meet leukemia oncologist Naval Daver, M.D.
Dr. Daver on Results of a Combination Study With Azacitidine/Nivolumab in AML
Dr. Daver on Results of a Combination Study With Azacitidine/Nivolumab in AML
Available and Emerging Nontargeted Therapies for AML — Naval Daver, MD
Available and Emerging Nontargeted Therapies for AML — Naval Daver, MD
Dr. Daver on the Utility of Maintenance Therapy in AML
Dr. Daver on the Utility of Maintenance Therapy in AML